Applied Genetic Technologies, a clinical-stage biotech developing treatments for orphan eye diseases, filed on Friday with the SEC to raise up to $70 million in an initial public offering. The Alachua, FL-based company, which was founded in 1999 and booked $1 million in grant and collaboration revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol AGTC. Barclays and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
